Vibostolimab is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 7 clinical trials, of which 5 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Vibostolimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Vibostolimab is expected to reach an annual total of $168 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vibostolimab (MK-7684) is under development for the treatment of solid tumors including melanoma, non-small cell lung cancer and adenocarcinoma of the gastroesophageal junction. The drug candidate is administered by intravenous route. It acts by targeting TIGIT protein.
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
The company reported revenues of (US Dollars) US$59,283 million for the fiscal year ended December 2022 (FY2022), an increase of 21.7% over FY2021. The operating profit of the company was US$18,152 million in FY2022, compared to an operating profit of US$12,538 million in FY2021. The net profit of the company was US$14,519 million in FY2022, compared to a net profit of US$13,049 million in FY2021.
For a complete picture of Vibostolimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.